Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 6Not yet recruiting 5Unknown 2Completed 2

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 40HER2 Positive Metastatic Breast Cancer 4Breast Diseases 4Brain Neoplasms 4Carcinoma, Non-Small-Cell Lung 3Stomach Neoplasms 2HER2-positive Breast Cancer 2Colorectal Neoplasms 2Advanced Breast Cancer 2Triple Negative Breast Neoplasms 1Solid Tumor 1Salivary Gland Neoplasms 1Pathologic Complete Response 1Neoplasm Metastasis 1Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer 1HER2-positive Metastatic Breast Cancer 1HER2+ Early or Locally Advanced Breast Cancer 1HER2+ Breast Cancer 1HER2 Positive Gastric Cancer 1HER2 Positive Breast Cancer 1HER-2 Positive Colorectal Cancer 1Estrogen Receptor-positive Breast Cancer 1Digestive System Neoplasms 1Carcinoma, Transitional Cell 1

Interventions

Trastuzumab 7Docetaxel 5pertuzumab 3pyrotinib 2neratinib 1liposomal doxorubicin 1envafolimab 1Protons 1Paclitaxel 1Metformin 1Carboplatin 1Capecitabine 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × HER2-positive Breast Cancer × pyrotinib × Clear all
NCT05561686 2022-09-30

Real-world Study of Pyrotinib in Neoadjuvant Therapy for HER2-positive Breast Cancer

Hunan Cancer Hospital

Unknown
100 enrolled
Breast

HER2-positive Breast Cancer

NCT05429294 2022-06-23

Novel Double Target Therapy Combined With Chemotherapy in First-line Treatment of HER2+ Breast Cancer, MA-BC-II-038

First Affiliated Hospital Xi'an Jiaotong University

Phase 2 Unknown
209 enrolled
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡